From the package insert at BMS, at the end in bold:
6.3 Additional Data From Clinical Trials
The following adverse reactions were reported in patients in the SPRYCEL clinical
studies at a frequency of 1%-<10%, 0.1%-<1%, or <0.1%. These events are
included on the basis of clinical relevance.
Gastrointestinal Disorders: 1%-<10% - mucosal inflammation (including mucositis/
stomatitis), dyspepsia, abdominal distension, constipation, gastritis, colitis (including
neutropenic colitis), oral soft tissue disorder; 0.1%-<1% - ascites, dysphagia, anal
fissure, upper gastrointestinal ulcer, esophagitis, pancreatitis; <0.1% - protein losing
gastroenteropathy.
General Disorders and Administration Site Conditions: 1%-<10% - asthenia, pain,
chest pain, chills; 0.1%-<1% - malaise, temperature intolerance.
Skin and Subcutaneous Tissue Disorders: 1%-<10% - pruritus, alopecia, acne, dry
skin, hyperhidrosis, urticaria, dermatitis (including eczema); 0.1%-<1% - pigmentation
disorder, skin ulcer, bullous conditions, photosensitivity, nail disorder, acute febrile
neutrophilic dermatosis, panniculitis, palmar-plantar erythrodysesthesia syndrome.
Respiratory, Thoracic, and Mediastinal Disorders: 1%-<10% - cough, lung
infiltration, pneumonitis, pulmonary hypertension; 0.1%-<1% - asthma,
bronchospasm; <0.1% - acute respiratory distress syndrome.
Nervous System Disorders: 1%-<10% - neuropathy (including peripheral neuropathy),
dizziness, dysgeusia, somnolence; 0.1%-<1% - amnesia, tremor, syncope; <0.1% -
convulsion, cerebrovascular accident, transient ischemic attack, optic neuritis.
Blood and Lymphatic System Disorders: 1%-<10% - pancytopenia; <0.1% -
aplasia pure red cell.
Musculoskeletal and Connective Tissue Disorders: 1%-<10% - muscular weakness; 0.1%-<1% - musculoskeletal stiffness, rhabdomyolysis; <0.1% - tendonitis.
Investigations: 1%-<10% - weight increased, weight decreased; 0.1%-<1% -
blood creatine phosphokinase increased.
Infections and Infestations: 1%-<10% - pneumonia (including bacterial, viral, and
fungal), upper respiratory tract infection/inflammation, herpes virus infection,
enterocolitis infection; 0.1%-<1% - sepsis (including fatal outcomes).